Ranbaxy will produce and market three HIV/AIDS drugs that currently are in late-stage clinical development by Gilead under a new licensing agreement between the drug makers.
Drug maker Gilead acknowledged the receipt of an unsolicited mini-tender offer by TRC Capital.
